Skip to main content

Drug Interactions between probenecid and valacyclovir

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

probenecid valACYclovir

Applies to: probenecid and valacyclovir

Probenecid may increase the serum concentration of acyclovir through competitive inhibition of renal tubular secretion. Initial dosage adjustments are not usually necessary, but patients should be monitored for acyclovir-related toxicities. Also, probenecid reduces the rate at which valacyclovir is converted to acyclovir. The extent of conversion, however, is unaffected. This interaction is not considered to be clinically significant.

References

  1. Laskin OL, de Miranda P, King DH, et al. (1982) "Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans." Antimicrob Agents Chemother, 21, p. 804-7
  2. (2001) "Product Information. Valtrex (valacyclovir)." Glaxo Wellcome
  3. Rolan PE, Maillot F, On NT, Posner J (1993) "The effects of cimetidine and probenecid on the conversion of a valine ester of acyclovir, 256U, to acyclovir and acyclovir renal clearance in healthy volunteers." Br J Clin Pharmacol, 33, p. 533

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer